Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
Sabine KahlAnne Pernille OfstadBernard ZinmanChristoph WannerElke SchuelerNaveed SattarCatherine M ViscoliMichael RodenPublished in: Diabetes, obesity & metabolism (2022)
Empagliflozin may reduce steatosis but not fibrosis risk in individuals with type 2 diabetes and cardiovascular disease. The improvements in cardiorenal outcomes and mortality associated with empagliflozin therapy appear to be independent of steatosis and fibrosis risk.